Vitamin D and Multiple Sclerosis
暂无分享,去创建一个
[1] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[2] M. Holick. Photosynthesis of vitamin D in the skin: effect of environmental and life-style variables. , 1987, Federation proceedings.
[3] H. DeLuca,et al. The response of intestinal calcium transport to 25-hydroxy and 1,25-dihydroxy vitamin D in nephrectomized rats. , 1972, Endocrinology.
[4] R. Loewenson,et al. The geographic distribution of multiple sclerosis: An examination of mathematical models☆ , 1973 .
[5] J. Wolinsky,et al. Measles encephalomyelitis--clinical and immunologic studies. , 1984, The New England journal of medicine.
[6] W. Sibley,et al. CLINICAL VIRAL INFECTIONS AND MULTIPLE SCLEROSIS , 1985, The Lancet.
[7] M. Holick,et al. Regulation of cutaneous previtamin D3 photosynthesis in man: skin pigment is not an essential regulator. , 1981, Science.
[8] G. Schwartz. Multiple sclerosis and prostate cancer: what do their similar geographies suggest? , 1992, Neuroepidemiology.
[9] H. Panitch. Influence of infection on exacerbations of multiple sclerosis , 2004, Annals of neurology.
[10] J. Bollerslev,et al. Down-regulation of monocyte functions by treatment of healthy adults with 1 alpha,25 dihydroxyvitamin D3. , 1991, International journal of immunopharmacology.
[11] B. Weinshenker,et al. Epidemiology of multiple sclerosis. , 1996, Neurologic clinics.
[12] D. Bates,et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. , 1989, Journal of neurology, neurosurgery, and psychiatry.
[13] G. Ulett. Geographic distribution of multiple sclerosis. , 1948, Diseases of the nervous system.
[14] J. Lemire. Immunomodulatory role of 1,25‐dihydroxyvitamin D3 , 1992, Journal of cellular biochemistry.
[15] K. Westlund. DISTRIBUTION AND MORTALITY TIME TREND OF MULTIPLE SCLEROSIS AND SOME OTHER DISEASES IN NORWAY , 1970, Acta neurologica Scandinavica.
[16] R. Swanborg,et al. Suppressor cell control of unresponsiveness to experimental allergic encephalomyelitis. , 1975, Journal of immunology.
[17] J. Haines,et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex , 1996, Nature Genetics.
[18] R. Zinkernagel,et al. The discovery of MHC restriction. , 1997, Immunology today.
[19] H. Weiner,et al. Prevention of experimental allergic encephalomyelitis (EAE) in the SJL/J mouse by whole body ultraviolet irradiation. , 1984, Journal of immunology.
[20] J. Kurtzke,et al. A method for estimating the age at immigration of white immigrants to South Africa, with an example of its importance. , 1970, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[21] H. Rieder,et al. The seasonal incidence of multiple sclerosis in Switzerland. , 1970, European neurology.
[22] D. Katz,et al. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. , 1987, Immunology.
[23] G. Schwartz. Hypothesis: calcitriol mediates pregnancy's protective effect on multiple sclerosis. , 1993, Archives of neurology.
[24] P. Goldberg. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence. (A viewpoint). Part 1. Sunlight, dietary factors and epidemiology. , 1974 .
[25] M. Brentani,et al. Sex steroids induced up-regulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[26] C. Davenport. MULTIPLE SCLEROSIS: FROM THE STANDPCINT OF GEOGRAPHIC DISTRIBUTION AND RACE , 1922 .
[27] M. Cippitelli,et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. , 1998, The Journal of clinical investigation.
[28] J. Strominger,et al. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases , 1995, The Journal of experimental medicine.
[29] J. Herbert,et al. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis , 1994, Neurology.
[30] A. Sadovnick,et al. The role of genetic factors in multiple sclerosis susceptibility , 1994, Journal of Neuroimmunology.
[31] P. Brachet,et al. Synthesis of 1,25‐dihydroxyvitamin D3 by rat brain macrophages in vitro , 1994, Journal of neuroscience research.
[32] J. Kurtzke. ON THE FINE STRUCTURE OF THE DISTRIBUTION OF MULTIPLE SCLEROSIS , 1967, Acta neurologica Scandinavica.
[33] B. Trapp,et al. Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis , 1996, Journal of Neuroimmunology.
[34] E. Kabat,et al. THE PATHOLOGY OF ACUTE DISSEMINATED ENCEPHALOMYELITIS PRODUCED EXPERIMENTALLY IN THE RHESUS MONKEY AND ITS RESEMBLANCE TO HUMAN DEMYELINATING DISEASE , 1947, Journal of neuropathology and experimental neurology.
[35] J. Adams,et al. INCREASED SKIN PIGMENT REDUCES THE CAPACITY OF SKIN TO SYNTHESISE VITAMIN D3 , 1982, The Lancet.
[36] P. Hjelmström,et al. A Critical Role for Lymphotoxin in Experimental Allergic Encephalomyelitis , 1997, The Journal of experimental medicine.
[37] J M Lemire,et al. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. , 1991, The Journal of clinical investigation.
[38] D. Hinds,et al. A full genome search in multiple sclerosis , 1996, Nature Genetics.
[39] R. Knobler,et al. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. , 1987, Clinical immunology and immunopathology.
[40] P. Henkart,et al. A protease-dependent TCR-induced death pathway in mature lymphocytes. , 1995, Journal of immunology.
[41] H. DeLuca,et al. Control of 25-hydroxycholecalciferol metabolism by parathyroid glands. , 1972, Proceedings of the National Academy of Sciences of the United States of America.
[42] M. Hutchinson,et al. Rate of Pregnancy-Related Relapse in Multiple Sclerosis , 1998 .
[43] L. Weiner,et al. Defective post–thymic tolerance mechanisms during the chronic progressive stage of multiple sclerosis , 1996, Nature Medicine.
[44] H. DeLuca,et al. 5,6-Trans-25-Hydroxycholecalciferol: Vitamin D Analog Effective on Intestine of Anephric Rats , 1972, Science.
[45] H. Newmark,et al. Vitamin D adequacy: a possible relationship to breast cancer. , 1994, Advances in experimental medicine and biology.
[46] H. DeLuca,et al. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[47] J. Demignon,et al. Effects of 1,25-dihydroxyvitamin D3 on in vitro lymphocyte reactions: arguments for a role at the maternofetal interface. , 1991, Gynecologic and obstetric investigation.
[48] C. C. Limburg. The geographic distribution of multiple sclerosis and its estimated prevalence in the United States. , 1950, Research publications - Association for Research in Nervous and Mental Disease.
[49] A. Meshorer,et al. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide , 1971, European journal of immunology.
[50] S. Tonegawa,et al. CD4+ T Cells Prevent Spontaneous Experimental Autoimmune Encephalomyelitis in Anti–Myelin Basic Protein T Cell Receptor Transgenic Mice , 1998, The Journal of experimental medicine.
[51] P. Goodfellow,et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22 , 1996, Nature Genetics.
[52] P. Malloy,et al. The Vitamin D Receptor Gene Start Codon Polymorphism: A Functional Analysis of FokI Variants , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[53] H. DeLuca,et al. Effect of vitamin D deficiency on fertility and reproductive capacity in the female rat. , 1980, The Journal of nutrition.
[54] M. Holick. PHOTOBIOLOGY, METABOLISM, AND CLINICAL ASPECTS OF VITAMIN D , 1981 .
[55] S. Manolagas,et al. Interactions of 1,25-dihydroxyvitamin D3 and the immune system , 1985, Molecular and Cellular Endocrinology.
[56] N. Roberts,et al. Seasonal Variation in Serum 25-Hydroxy Vitamin D3 Does Not Affect 1,25-Dihydroxy Vitamin D , 1994, Annals of clinical biochemistry.
[57] H. Deluca. Vitamin D: 1993 , 1993 .
[58] W. Stumpf,et al. Vitamin D (soltriol), light, and reproduction. , 1989, American journal of obstetrics and gynecology.
[59] H. DeLuca,et al. 1α,25-dihydroxyvitamin D3 a nd 19-nor-1α,25-dihydroxyvitamin 32 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo , 1993 .
[60] S. Fey,et al. MS and the group‐specific component , 1988, Acta neurologica Scandinavica.
[61] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[62] Y. Taketani,et al. A Vitamin D Receptor Gene Polymorphism in the Translation Initiation Codon: Effect on Protein Activity and Relation to Bone Mineral Density in Japanese Women , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[63] R. Swank,et al. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. , 1952, The New England journal of medicine.
[64] S. Krane,et al. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. , 1983, The Journal of clinical endocrinology and metabolism.
[65] J. Adams,et al. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. , 1983, The Journal of clinical investigation.
[66] H. DeLuca. Vitamin D: the vitamin and the hormone. , 1974, Federation proceedings.
[67] H. DeLuca,et al. Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. , 1979, The Journal of clinical investigation.
[68] F. Sánchez‐Madrid,et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin , 1992, Nature.
[69] J. W. Rose,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.
[70] G. Dean,et al. Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa. , 1967, British medical journal.
[71] J. Presthus. REPORT ON THE MULTIPLE SCLEROSIS INVESTIGATIONS IN WEST‐NORWAY , 1960, Acta psychiatrica Scandinavica. Supplementum.
[72] I. Weissman,et al. Infection and multiple sclerosis: a possible role for superantigens? , 1994, Trends in microbiology.
[73] H. DeLuca,et al. Two Vitamin D Response Elements Function in the Rat 1,25-Dihydroxyvitamin D 24-Hydroxylase Promoter (*) , 1995, The Journal of Biological Chemistry.
[74] W. Karpus,et al. CD4+ suppressor cells differentially affect the production of IFN-gamma by effector cells of experimental autoimmune encephalomyelitis. , 1989, Journal of immunology.
[75] H. DeLuca,et al. 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. , 1998, Journal of immunology.
[76] J. Lafaille,et al. Regulatory Cd4 Ϩ T Cells Expressing Endogenous T Cell Receptor Chains Protect Myelin Basic Protein–specific Transgenic Mice from Spontaneous Autoimmune Encephalomyelitis , 1998 .
[77] L Steinman,et al. Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System , 1996, Cell.
[78] H. DeLuca. The vitamin D story: a collaborative effort of basic science and clinical medicine 1 , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[79] G. Beebe,et al. Epidemiology of multiple sclerosis in U.S. veterans: 2. Latitude, climate and the risk of multiple sclerosis. , 1983, Journal of chronic diseases.
[80] H. DeLuca,et al. Molecular biology of vitamin D action. , 1994, Vitamins and hormones.
[81] P. Goldberg,et al. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. , 1986, Medical hypotheses.
[82] H. Link,et al. Distribution of group‐specific component subtypes in multiple sclerosis , 1988, Acta Neurologica Scandinavica.
[83] P. Brachet,et al. 1,25 Dihydroxyvitamin D3 Exerts Regional Effects in the Central Nervous System during Experimental Allergic Encephalomyelitis , 1996, Journal of neuropathology and experimental neurology.
[84] J. Pike,et al. Vitamin D3 receptors: structure and function in transcription. , 1991, Annual review of nutrition.
[85] J. Zerwekh,et al. Pathogenetic Role of lα,25-Dihydroxyvitamin D inarcoidosis and Absorptive Hypercalciuria: DifferentResponse to Prednisolone Therapy* , 1980 .
[86] G. Harrell,et al. BLOOD CHEMICAL CHANGES IN BOECK'S SARCOID WITH PARTICULAR REFERENCE TO PROTEIN, CALCIUM AND PHOSPHATASE VALUES. , 1939, The Journal of clinical investigation.
[87] S. Epstein,et al. Evidence for alteration of the vitamin D-endocrine system in blacks. , 1985, The Journal of clinical investigation.
[88] E. Shevach,et al. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. , 1998, Journal of immunology.
[89] S. Manolagas,et al. 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. , 1984, Science.
[90] R. Bouillon,et al. Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 α, 25-(OH)2D3 , 1995, Journal of Neuroimmunology.
[91] S. Manolagas,et al. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. , 1983, Science.
[92] H. Weiner,et al. IL-10 is critical in the regulation of automimmune encephalomyelitis as demonstrated by studies of IL-10 and IL-4 deficient and transgenic mice , 1998, Journal of Neuroimmunology.
[93] M. Holick,et al. The cutaneous photosynthesis of previtamin D3: a unique photoendocrine system. , 1981, The Journal of investigative dermatology.
[94] J. Herbert,et al. High‐dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[95] A. Sadovnick,et al. The geographic distribution of multiple sclerosis: a review. , 1993, Neuroepidemiology.
[96] N. Bell. Bone and mineral metabolism in African Americans , 1997, Trends in Endocrinology & Metabolism.
[97] C. Kovacs,et al. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. , 1997, Endocrine reviews.
[98] S. Manolagas,et al. 1α,25-Dihydroxyvitamin D3 Receptor Distribution and Effects in Subpopulations of Normal Human T Lymphocytes* , 1989 .
[99] T. Markestad,et al. Effect of estrogen on vitamin D metabolism in tall girls. , 1983, The Journal of clinical endocrinology and metabolism.
[100] P. Goldberg. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence: (A viewpoint) part 2. biochemical and genetic factors , 1974 .
[101] J. Kurtzke. Epidemiologic evidence for multiple sclerosis as an infection , 1993, Clinical Microbiology Reviews.
[102] E. Acheson,et al. SOME COMMENTS ON THE RELATIONSHIP OF THE DISTRIBUTION OF MULTIPLE SCLEROSIS TO LATITUDE, SOLAR RADIATION, AND OTHER VARIABLES , 1960, Acta psychiatrica Scandinavica. Supplementum.
[103] J. Adams,et al. Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis , 1985, The Journal of experimental medicine.
[104] H. DeLuca,et al. Vitamin D: recent advances. , 1983, Annual review of biochemistry.
[105] M. Holick. 1,25-Dihydroxyvitamin D3 and the Skin: A Unique Application for the Treatment of Psoriasis , 1989, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[106] T. Mosmann,et al. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. , 1990, Science.
[107] T. Riise,et al. Incidence of multiple sclerosis in Møre and Romsdal, Norway from 1950 to 1991. An age-period-cohort analysis. , 1996, Brain : a journal of neurology.
[108] W. Sibley,et al. Seasonal variation of multiple sclerosis exacerbations in Arizona , 1983, Neurology.
[109] T. Clemens,et al. 1, 25-DIHYDROXYCHOLECALCIFEROL IN THE PATHOGENESIS OF THE HYPERCALCÆMIA OF SARCOIDOSIS , 1979, The Lancet.
[110] J. Herbert,et al. Fracture history and bone loss in patients with MS , 1998, Neurology.
[111] L. Kurland. The frequency and geographic distribution of multiple sclerosis as indicated by mortality statistics and morbidity surveys in the United States and Canada. , 1952, American journal of hygiene.
[112] J. Peters,et al. 1,25‐Dihydroxyvitamin D3 Exerts Opposing Effects to IL‐4 on MHC Class‐II Antigen Expression, Accessory Activity, and Phagocytosis of Human Monocytes , 1993, Scandinavian journal of immunology.
[113] Justin M. Nolan,et al. Measurement of circulating vitamin D in man. , 1982, Clinica chimica acta; international journal of clinical chemistry.
[114] J. Studd,et al. A Pilot Study of the Effect upon Multiple Sclerosis of the Menopause, Hormone Replacement Therapy and the Menstrual Cycle , 1992, Journal of the Royal Society of Medicine.
[115] S. Miller,et al. The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases. , 1994, Immunology today.